Sep 28, 2021 / 05:00PM GMT
Presentation Part 2: DetermaIO⢠in Triple-Negative Breast Cancer
Sep 28, 2021 / 05:00PM GMT
=====================
Corporate Participants
=====================
* Robert S. Seitz
OncoCyte Corporation - Head of Immune Oncology
* Ronald A. Andrews
OncoCyte Corporation - CEO, President & Director
=====================
Conference Call Participants
=====================
* Bruce David Jackson
The Benchmark Company, LLC, Research Division - Senior Equity Analyst
* Mark Anthony Massaro
BTIG, LLC, Research Division - MD & Life Science & Diagnostic Tools Analyst
* Michael Stephen Matson
Needham & Company, LLC, Research Division - Senior Analyst
* Thomas Flaten
Lake Street Capital Markets, LLC, Research Division - Senior Research Analyst
* Giampaolo Bianchini
* Priyanka Sharma
=====================
Operator
Good afternoon, and welcome to the Oncocyte KOL Event Series, Part 2 on DetermaIO in Triple-Negative Breast Cancer. (Operator
OncoCyte Corp Key Opinion Leader Presentation Part 2: DetermaIO™ in Triple-Negative Breast Cancer Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
